Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades Bionomics to Neutral

HC Wainwright & Co. Downgrades Bionomics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Bionomics (NASDAQ:BNOX) from Buy to Neutral.

byBenzinga Newsdesk

December 19, 2022

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis downgrades Bionomics (NASDAQ:BNOX) from Buy to Neutral.

Analyst Ratings

5 Analysts Have This to Say About Quest Diagnostics

By Benzinga Insights

January 23, 2:00 PM

Over the past 3 months, 5 analysts have published their opinion on Quest Diagnostics (NYSE:DGX) stock. These analysts…

DGX

Benchmark Initiates Coverage On NOW with Buy Rating, Announces Price Target of $13

By Benzinga Newsdesk

July 8, 5:01 AM

Benchmark analyst Douglas Becker initiates coverage on NOW (NYSE:DNOW) with a Buy rating and announces Price Target of $13.

DNOW

News

A Look Into Utilities Sector Value Stocks

By Benzinga Insights

December 6, 10:38 AM

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices…

BEPC

Apple’s Timepiece Trouble: Patent Dispute Puts Apple Watch Imports in Jeopardy

By Benzinga Neuro

October 27, 6:29 AM

The U.S. International Trade Commission may ban the import of Apple Watches due to a patent infringement dispute with medical tech firm Masimo, pending a presidential review and potential appeals.

AAPL

HC Wainwright & Co. Downgrades Bionomics to Neutral

Related Posts

5 Analysts Have This to Say About Quest Diagnostics

Benchmark Initiates Coverage On NOW with Buy Rating, Announces Price Target of $13

A Look Into Utilities Sector Value Stocks

Apple’s Timepiece Trouble: Patent Dispute Puts Apple Watch Imports in Jeopardy